ARTICLE | Clinical News
NBS-101: Phase I data
October 3, 2005 7:00 AM UTC
In a Danish Phase I trial in 60 patients, NPS-101 showed bioequivalence at a lower dose than the approved 2 g dose of strontium ranelate. The company said it will allow for once-daily dosing. Also, NB...